Related Experiment Videos
Thymostimulin administration modulates polymorph metabolic pathway in patients with chronic obstructive pulmonary
C Tortorella1, A Ottolenghi, A M Moretti
1University of Bari Medical Faculty, Policlinico, Italy.
Immunopharmacology and Immunotoxicology
|January 1, 1992
Summary
Thymostimulin treatment normalized immune cell functions and improved clinical status in chronic obstructive pulmonary disease (COPD) patients. This suggests thymostimulin may be a beneficial therapy for COPD management.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Phagocyte dysfunction is a hallmark of chronic obstructive pulmonary disease (COPD).
- Understanding immune cell responses in COPD is crucial for developing effective treatments.
Purpose of the Study:
- To evaluate the effects of thymostimulin on monocyte and polymorphonuclear cell (PMN) functions in COPD patients.
- To assess changes in PMN-metabolic pathways and clinical status following thymostimulin administration.
Main Methods:
- Assessed monocyte and PMN chemotactic, phagocytic, and killing capacities before and after thymostimulin treatment.
- Measured PMN-triggered metabolic pathways, including O2- generation and myeloperoxidase release.
- Monitored clinical status of COPD patients over a one-year period post-immunotherapy.
Main Results:
- COPD patients initially showed increased O2- generation and decreased myeloperoxidase release, with reduced PMN chemotaxis/killing and monocyte chemotaxis.
- Thymostimulin therapy normalized O2- production and myeloperoxidase activity within one year.
- Phagocyte functional capacities remained largely unaffected, but clinical status significantly improved.
Conclusions:
- Thymostimulin may play a beneficial role in managing COPD by restoring certain immune cell functions.
- The observed clinical improvement suggests thymostimulin's potential as a therapeutic agent for COPD patients.